News - regorafenib, Research

Filter

Current filters:

regorafenibResearch

Popular Filters

News briefs: US priority review for regorafenib; Ph IIb blisibimod data

29-06-2012

Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

More news from ASCO meeting

05-06-2012

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

News briefs: GlaxoSmithKline and Bayer

24-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Bayer cancer drug candidate regorafenib improves survival in GIST

04-04-2012

German drug major Bayer (BAY: DE) yesterday announced positive results from its Phase III trial GRID…

BayerOncologyPharmaceuticalregorafenibRegulationResearch

Bayer’s Xarelto OKed in Japan; promising regorafenib data

19-01-2012

Bayer Healthcare, a unit of Germany’s Bayer AG (BAY: DE), had a couple of good news item to report…

BayerCardio-vascularOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationResearchXarelto

Bayer boasts four potential pipeline blockbusters

21-12-2011

German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue…

AlpharadinBayerCardio-vascularEyleaFinancialMarkets & MarketingOncologyOphthalmicsPharmaceuticalregorafenibResearchXarelto

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

27-10-2011

USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Back to top